Awakening the “guardian of genome”: reactivation of mutant p53 Akshay BinaykeSarthak MishraHarish Chander Review Article 15 October 2018 Pages: 1 - 15
Autophagy and its potent modulators from phytochemicals in cancer treatment Chao-Yue SunQian-Yu ZhangBing Feng Review Article 23 October 2018 Pages: 17 - 26
Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters Laure DeymeDominique BarbolosiFlorence Gattacceca Review Article 16 November 2018 Pages: 27 - 42
Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET Susumu HijiokaKeiichiro SakumaYasushi Yatabe Original Article 11 October 2018 Pages: 43 - 52
Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy Jacob NerstingStine Nygaard Nielsenthe Nordic Society of Paediatric Haematology and Oncology (NOPHO) Original Article 15 October 2018 Pages: 53 - 60
Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients Brittney R. StarlingParag KumarWilliam C. Zamboni Original Article 16 October 2018 Pages: 61 - 70
Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis Yu BaiHai-wei WuYan-hua Zhang Original Article 24 October 2018 Pages: 71 - 79
Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats Priyanka AroraCourtney Huff AdamsPankaj B. Desai Original Article 24 October 2018 Pages: 81 - 89
Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers Nathalie RiouxAmy KimJoanne Schindler Original Article 27 October 2018 Pages: 91 - 96
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103) Kristina LindemannPhilip J. BealeFor ANZGOG and HCRN Collaborative Groups Original Article 27 October 2018 Pages: 97 - 105
Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms Akimitsu MaedaKei IrieShoji Fukushima Original Article 27 October 2018 Pages: 107 - 113
Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? Osman KöstekMuhammet Bekir HacıoğluBülent Erdoğan Original Article 29 October 2018 Pages: 115 - 122
Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer Hironori FujiiYunami YamadaAkio Suzuki Original Article Open access 30 October 2018 Pages: 123 - 129
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes Ece EsinB. OksuzogluTurkish Oncology Group Original Article 30 October 2018 Pages: 131 - 143
Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial Koji MuronoHiroshi NagataSoichiro Ishihara Original Article 01 November 2018 Pages: 145 - 150
Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA) Nathalie RiouxSherri SmithPeter G. Smith Original Article 01 November 2018 Pages: 151 - 160
A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer Yasushi SatoTamotsu SagawaTetsuji Takayama Original Article 07 November 2018 Pages: 161 - 167
Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics I. KümlerP. Grundtvig SørensenD. L. Nielsen Original Article Open access 08 November 2018 Pages: 169 - 178
Steroidal dimer by001 inhibits proliferation and migration of esophageal cancer cells via multiple mechanisms Sai-Qi WangKai-Rui ZhouXiao-Bing Chen Original Article 08 November 2018 Pages: 179 - 189
Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma Robin L. JonesGary MoWilliam D. Tap Original Article Open access 08 November 2018 Pages: 191 - 199
Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study Kazuo SatoYasuharu ToyoshimaEmiko Ohki Original Article Open access 09 November 2018 Pages: 201 - 207
Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients W. Venus SoTai-Hsien Ou YangJianguo Zhi Short Communication Open access 03 December 2018 Pages: 209 - 213
Correction to: Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice Soumaya LabidiNesrine MejriHamouda Boussen Correction 10 December 2018 Pages: 215 - 215